Global Health Developments: Deals, Dramatics, and Discoveries

LEO Pharma plans to acquire the U.S. drug developer Replay for $50 million upfront, enhancing its offerings in dermatology with an innovative platform for rare genetic skin diseases. Bristol Myers Squibb outperformed profit expectations due to strong sales of blood thinner and cancer drugs. In other news, Cardinal Health's revenue outlook was clouded by recent legislative changes, while the Canadian health regulator approved a second generic version of Novo Nordisk’s Ozempic.

The Danish company LEO Pharma is stepping up its dermatological game by acquiring U.S. drug developer Replay for $50 million upfront, also agreeing to undisclosed milestone payments and royalties. This acquisition, announced on Thursday, is set to boost its treatment platform for rare genetic skin diseases.

Bristol Myers Squibb has exceeded Wall Street's quarterly profit projections, driven by impressive sales of its blood thinner Eliquis and emerging cancer drugs. This financial triumph pushed company shares up 4% as the revenue hit $11.49 billion, surpassing an anticipated $10.9 billion.

Meanwhile, Cardinal Health's financial prospects took a hit when its third-quarter revenue fell short, resulting in an 8% drop in shares. Despite its optimistic profit forecast revisions, pharmaceutical revenue was deterred by regulatory changes from the Inflation Reduction Act.